

**THOMAS IRA MARGOLIS, M. D.**

**OFFICE ADDRESS:**

1500 Tilton Road  
Northfield, NJ 08225  
609-646-5200  
FAX 609-646-9868

2466 E. Chestnut Ave.  
Vineland, NJ 08361  
856-507-0020  
FAX 856-507-0040

211 S. Main St. suite 102  
Cape May Court House  
NJ 08210 609-463-4610  
FAX 609-463-4616

**PROFESSIONAL EXPERIENCE**

RETINAL AND OPHTHALMIC CONSULTANTS, PC, Northfield, NJ, 1995 - Present.  
Private group practice limited to vitreoretinal diseases and surgery. Participation in clinical trials.

**EDUCATION**

HARVARD MEDICAL SCHOOL, Boston, MA, 1984-1989. MD, Magna Cum Laude.  
Honors thesis: "New Mid-Infrared Lasers for Vitreous Membrane Cutting and Sclerostomy".

UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA, 1980-84. BA in Economics and Chemistry (with honors). Summa Cum Laude.

UNIONTOWN AREA SENIOR HIGH SCHOOL, Uniontown, PA. Valedictorian, 1980.

**POSTGRADUATE TRAINING**

NEW ENGLAND EYE CENTER, TUFTS UNIVERSITY SCHOOL OF MEDICINE, Boston, MA, 1993-1995. Vitreoretinal fellowship.

WILLS EYE HOSPITAL, THOMAS JEFFERSON UNIVERSITY SCHOOL OF MEDICINE, Philadelphia, PA, 1990-1993. Ophthalmology residency.

CEDARS-SINAI MEDICAL CENTER, UCLA SCHOOL OF MEDICINE, Los Angeles, CA, 1989-90. Internal medicine internship.

MASSACHUSETTS EYE AND EAR INFIRMARY, HARVARD MEDICAL SCHOOL, Boston, MA. Laser research fellowship. 1987-1988.

**ACADEMIC APPOINTMENT**

TUFTS UNIVERSITY SCHOOL OF MEDICINE: Instructor-in-Ophthalmology, 1993-1995.

**HOSPITAL APPOINTMENTS**

SHORE MEMORIAL HOSPITAL, Somers Point, NJ: Attending Ophthalmologist, 1995-present.

ATLANTICARE REGIONAL MEDICAL CENTER, Atlantic City, NJ: Attending Ophthalmologist, 1995-present.

BETTY BACHARACH REHABILITATION HOSPITAL, Pomona, NJ: Consulting Ophthalmologist, 1995-present.

NEW ENGLAND MEDICAL CENTER, Boston, MA: Assistant-in-Ophthalmology, 1993-1995.

MASSACHUSETTS EYE AND EAR INFIRMARY, Boston, MA: Assistant-in-Ophthalmology, 1994-1995.

BOSTON VETERANS ADMINISTRATION MEDICAL CENTER, Boston, MA: Attending Ophthalmologist, 1993-1995.

### **RESEARCH EXPERIENCE**

#### VIEW 1 Extension – Principle Investigator

Regeneron

2010-Present

Protocol: VGFT-OD-0910

Open-label, long-term, safety and tolerability extension study of intravitreal VEGF Trap-Eye in neovascular age-related macular degeneration.

#### NAION-Sub- Investigator

Covance

2009-Present

Protocol: 12912

Prospective case crossover study to assess whether PDE5 inhibitor exposure in men with erectile dysfunction increases the risk for the development of non-arteritic anterior ischemic optic neuropathy (NAION).

#### HORIZON- Sub-Investigator

Genentech

2009- Present

Protocol: FVF3426G

An open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) or macular edema secondary to retinal vein occlusion (RVO) who have completed a Genentech sponsored ranizumab study.

#### COPERNICUS-Principle-Investigator

Regeneron

2009-Present  
Protocol: VGFT-OD-0819

Randomized, Double-masked, controlled phase III study of the efficacy, safety and tolerability of repeated administration of VEGF Trap-Eye in subjects with macular edema secondary to central retinal vein occlusion (CRVO).

HARBOR-Sub-Investigator

Genentech  
2009-2010  
Protocol: FVF4579G

Phase III, double-masked, multi-center, randomized, active treatment, controlled study of the efficacy and safety of 0.5 mg and 2.0 mg Ranibizumab; administered monthly or on an as-needed-basis (PRN) in patients with subfoveal neovascular age-related macular degeneration.

DAVINCI- Principle Investigator

Regeneron  
2008-Present  
Protocol: VGFT-OD-0706

A double-masked, randomized, controlled study of the safety, tolerability and biological effect of repeated intravitreal administration of VEGF Trap-Eye in patients with diabetic macular edema (DME).

RISE – Sub-Investigator

Genentech  
2008 – Present  
Protocol: FVF4170G

3 year multi center study with monthly visits for patients with Diabetic Macular Edema comparing Lucentis with Standard of Care Laser treatments.

CRUISE – Sub-Investigator

Genentech  
2008 – 2010  
Protocol: FVF41669

1 year multi center study with monthly visits comparing Lucentis to sham procedure for patients with central retinal vein occlusion.

VIEW1 – Principle Investigator

Regeneron  
2007 – Present  
Protocol: VGFT-OD-0605

2 year multi center study with monthly visits comparing VEGF-Trap against Lucentis for patients with newly diagnosed age-related macular degeneration.

SIRIUS – Principle Investigator

Allergan

2006 – 2008  
Protocol: 211745-001-01

2 year multi center study comparing Sirna against Lucentis for age-related macular degeneration

NOTAL VISION HMP-V4 – Sub-Investigator

Notal Vision  
2006-2007  
Protocol: 20071801

Sensitivity of the Home Macular Perimeter (HMP) in detection of choroidal neovascularization (CNV) secondary to age-related macular degeneration (ARMD)

SAILOR – Sub-Investigator

Genentech, Inc.  
2003 – 2007  
Protocol: FVF3689G

1 year multi center study to evaluate the safety and tolerability of Lucentis in newly diagnosed and previously treated subjects with age-related macular degeneration.

RhuFab V2 (ranibizumab) – Principle Investigator

Genentech, Inc.  
2003 - 2005  
Protocol FVF2587g

A phase III, multicenter, randomized, double-masked, active treatment-controlled study of the efficacy and safety of rhuFab V2 (ranibizumab) compared with verteporfin (Visudyne) photodynamic therapy in subjects with predominantly classic subfoveal neovascular age-related macular degeneration.

Verteporfin Photodynamic Therapy - Principle Investigator

Ciba Vision  
1999 - 2000  
Protocol BPD OCR 005

An open-label, multicenter, safety study of the treatment of predominantly classic subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) using photodynamic therapy with verteporfin for injection.

Flibanserin

University of Pennsylvania and Boehringer Ingelheim (BI Trial No. 511.11)  
1997-8

An eight-week, double-blind, placebo controlled Phase II study of various doses of flibanserin and paroxetine in patients with Major Depressive Disorder. Our role was to perform ophthalmic examinations to evaluate for potential ocular complications and side effects.

Pioglitazone

Takeda America, Inc.

1996

A double-blind placebo-controlled, randomized, dose-titration study to evaluate the safety and efficacy of pioglitazone, an oral hypoglycemic agent. Our role was to perform retinal examinations and evaluate retinal photographs for evidence of diabetic retinopathy.

Adefovir Dipivoxil (bis-POM PMEA)

NJCRI

1996-7

A placebo-controlled study of the safety and efficacy of adefovir dipivoxil (bis-POM PMEA) in prolonged survival of HIV-infected individuals with a CD4+ cell count of  $\leq 100/\text{mm}^3$ . Our role was for ophthalmic evaluation with emphasis on the presence or absence of CMV retinitis.

WILMER EYE INSTITUTE, JOHNS HOPKINS UNIVERSITY. Acted as a field supervisor in Liberia for a large scale clinical trial of ivermectin in the treatment of onchocerciasis. 1988.

BRIGHAM AND WOMEN'S HOSPITAL, Boston, MA. Biomedical research on the effects of acidosis on cultured ventricular cells, 1985.

**CERTIFICATION AND LICENSURE**

New Jersey 1991-present

Pennsylvania 1991-present

Massachusetts Inactive

American Board of Ophthalmology, Diplomate 1995, Recertified 2005

National Board of Medical Examiners, Diplomate 1990

Certified examiner for STOP-ROP Study (Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity) 1993-1995

**AWARDS AND HONORS**

Marquis Who's Who in America, 2004-2006, 2008-2011

*Philadelphia Magazine*, "Top Docs", 2004 - 2010

*New Jersey Monthly*, "The Best Doctors in New Jersey", September, 2003 and September, 2005

*New Jersey Life Magazine*, "Top Docs", March, 2005

"America's Top Ophthalmologists", Consumer's Research Council of America, 2004 - 2008

Strathmore's Who's Who, 2005-2006

National Register's WHO'S WHO IN EXECUTIVES & PROFESSIONALS, 2004 - 2006

Laurence B. Ellis Scholar-Harvard Medical School-1987-88

Soma Weiss Assembly-Harvard Medical School-1986, 1989

Merck Senior Chemistry Award-University of Pennsylvania- 1984

Phi Beta Kappa-1983

Benjamin Franklin Scholar-University of Pennsylvania-1980-84

Alpha Epsilon Delta Pre-Medical Honor Society-1983

**MAJOR MEMBERSHIPS/COMMITTEES**

Atlantic County Medical Society 1995 – present  
President 2007-8; Executive Committee, 2003 - present  
Medical Society of New Jersey, Credentials Committee, 2001 - present  
New Jersey Medical Board, Expert Reviewer, 1995 - present  
American Society of Retina Specialists 1996 - present  
Retina Society of New Jersey 1995 - present  
New Jersey Academy of Ophthalmology 1995 - present  
Medical Society of New Jersey 1995 - present  
Wills Eye Hospital Society 1993 - present  
American Academy of Ophthalmology 1990 - present  
American Medical Association 1989 - present  
Association for Research in Vision and Ophthalmology 1988 - 2002  
University of Pennsylvania Career Network Advisor 1995 - present

## **BIBLIOGRAPHY**

### Articles

Duker, JS, **Margolis TI**: How to treat BRVO. Rev Ophthalmol 1995; 2 (12):50-51.

Avvad FK, Duker JS, Reichel E, **Margolis TI**, Puliafito CA: The digital indocyanine green videoangiography characteristics of well-defined choroidal neovascularization. Ophthalmol 1995; 102:401-405.

**Margolis TI**, Duker JS: Review of "Atlas of Intraocular Tumors". Am J Ophthalmol 1994; 118:688.

**Margolis TI**, Duker JS: Laser treatment of retinal vein occlusion. Ophthalmic Practice 1994; 12 (1):8-12,42.

Borirakchanyavat S, Puliafito CA, Kliman GH, **Margolis TI**, Galler E: Holmium-YAG laser surgery on experimental vitreous membranes. Arch Ophthalmol 1991; 109:1605-1609.

**Margolis TI**, Farnath DA, Destro M, Puliafito CA: Erbium-YAG laser surgery on experimental vitreous membranes. Arch Ophthalmol 1989; 107:424-428.

Marsh JD, **Margolis TI**, Kim D: Mechanism of diminished contractile response to catecholamines during acidosis. Am J Physiol 1988; 254:H20-27.

### Chapters

**Margolis TI**: Contributor to ten sections in Retina and Uveitis chapters. In: Cullum RD and Chang B, ed., The Wills Eye Manual-Office and Emergency Room Diagnosis and Treatment of Eye Disease. Second Edition. J. B. Lippincott Co., Philadelphia, 1994.

### Abstracts

**Margolis TI**, Duker JS, Reichel E, Rutledge BK, Morley MG, Davis JL: Repair of retinal detachments related to cytomegalovirus retinitis in eyes with ganciclovir implants. Invest Ophthalmol Vis Sci 1995; 36(4):S778.

Jivanjee SQ, Duker JS, **Margolis TI**, Reichel E, Puliafito CA, Morley MG: Pneumatic buckle: an alternative technique for the treatment of retinal detachment without subretinal fluid drainage. Invest Ophthalmol Vis Sci 1995; 36(4):S850.

Rutledge BK, Morley MG, Duker JS, **Margolis TI**: Combination antiviral therapy for the progressive outer retinal necrosis syndrome. Invest Ophthalmol Vis Sci 1995; 36(4):S318.

**Margolis TI**, Duker JS, Reichel E, Puliafito CA: Indirect diode laser photocoagulation for threshold and posterior prethreshold retinopathy of prematurity. Invest Ophthalmol Vis Sci 1994; 35(4):1443.

**Margolis TI**, Farnath DA, Puliafito CA: Mid-infrared laser sclerostomy. Invest Ophthalmol Vis Sci 1988; 29 (supp):366.

Farnath, DA, **Margolis TI**, Destro M, Puliafito CA: Erbium-YAG laser surgery on experimental vitreous membranes in rabbits. Invest Ophthalmol Vis Sci 1988; 29 (supp):292.

Borirak S, **Margolis TI**, Kliman GH, Puliafito CA: Holmium-YAG laser surgery on experimental vitreous membranes in rabbits. Invest Ophthalmol Vis Sci 1989; 30 (supp):372.